Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment

Author:

Bullen AlistairORCID,Ryan Mandy,Ennis Holly,Gray Ewan,Loría-Rebolledo Luis EnriqueORCID,McIntyre Morag,Hall Peter

Abstract

ObjectivesThere has been a recent proliferation in treatment options for patients with metastatic breast cancer. Such treatments often involve trade-offs between overall survival and side effects. Our study aims to estimate the trade-offs that could be used to inform decision-making at the individual and policy level.DesignWe designed a discrete choice experiment (DCE) to look at preferences for avoiding severity levels of side effects when choosing treatment for metastatic breast cancer. Treatment attributes were: fatigue, nausea, diarrhoea, other side effects (peripheral neuropathy, hand–foot syndrome and mucositis) and urgent hospital admission and overall survival. Responses were analysed using an error component logit model. We estimated the relative importance of attributes and minimum acceptable survival for improvements in side effects.SettingThe DCE was completed online by UK residents with self-reported diagnoses of breast cancer.Participants105 respondents participated, of which 72 patients had metastatic breast cancer and 33 patients had primary breast cancer.ResultsOverall survival had the largest relative importance, followed by other side effects, diarrhoea, nausea and fatigue. The risk of urgent hospital admission was not significant. While overall survival was the most important attribute, respondents were willing to forgo some absolute probability of overall survival for reductions in all Grade 2 side effects (12.02% for hand–foot syndrome, 11.01% for mucositis, 10.42% for peripheral neuropathy, 6.33% for diarrhoea and 3.62% for nausea). Grade 1 side effects were not significant, suggesting respondents have a general tolerance for them.ConclusionsPatients are willing to forgo overall survival to avoid particular severity levels of side effects. Our results have implications for data collected in research studies and can help inform person-centred care and shared decision-making.

Funder

Edinburgh and Lothians Health Foundation

University of Aberdeen

Chief Scientist Office of the Scottish Government

Cancer Research UK

Publisher

BMJ

Reference48 articles.

1. Number of UK patients with metastatic breast cancer isn’t known;Feinmann;BMJ,2017

2. Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients;Brom;PLoS One,2014

3. Breast Cancer Treatment

4. Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae;Mosher;Breast J,2013

5. Scottish Government . What Works to Support and Promote Shared Decision Making: A synthesis of recent evidence, 2019. Available: https://www.gov.scot/publications/works-support-promote-shared-decision-making-synthesis-recent-evidence/pages/3 [Accessed 7 Mar 2022].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3